GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)

Hisashi Kawazoe; Vladimir N. Bilim; Andrey V. Ugolkov; Kaori Yuuki; Sei Naito; Akira Nagaoka; Tomoyuki Kato; Yoshihiko Tomita

doi:10.1016/j.bbrc.2012.05.147

GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)

Hisashi Kawazoe, Vladimir N. Bilim, Andrey V. Ugolkov, Kaori Yuuki, Sei Naito, Akira Nagaoka, Tomoyuki Kato, Yoshihiko Tomita^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Sorafenib is a multikinase inhibitor approved for the systemic treatment of renal cell carcinoma (RCC). However, sorafenib treatment has a limited effect due to acquired chemoresistance of RCC. Previously, we identified glycogen synthase kinase-3 (GSK-3) as a new therapeutic target in RCC. Here, we observed that sorafenib inhibits proliferation and survival of RCC cells. Significantly, we revealed that sorafenib enhances GSK-3 activity in RCC cells, which could be a potential mechanism of acquired chemoresistance. We found that pharmacological inhibition of GSK-3 potentiates sorafenib antitumor effect in vitro and in vivo. Our results suggest that combining GSK-3 inhibitor and sorafenib might be a potential new therapeutic approach for RCC treatment.

Original language	English (US)
Pages (from-to)	490-495
Number of pages	6
Journal	Biochemical and Biophysical Research Communications
Volume	423
Issue number	3
DOIs	https://doi.org/10.1016/j.bbrc.2012.05.147
State	Published - Jul 6 2012

Keywords

Glycogen synthase kinase-3
Renal cell carcinoma
Sorafenib
Tyrosine kinase inhibitor

ASJC Scopus subject areas

Biophysics
Biochemistry
Molecular Biology
Cell Biology

Access to Document

10.1016/j.bbrc.2012.05.147

Cite this

@article{ce81731dd26945a789bfd9c4f7f8e426,

title = "GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)",

abstract = "Sorafenib is a multikinase inhibitor approved for the systemic treatment of renal cell carcinoma (RCC). However, sorafenib treatment has a limited effect due to acquired chemoresistance of RCC. Previously, we identified glycogen synthase kinase-3 (GSK-3) as a new therapeutic target in RCC. Here, we observed that sorafenib inhibits proliferation and survival of RCC cells. Significantly, we revealed that sorafenib enhances GSK-3 activity in RCC cells, which could be a potential mechanism of acquired chemoresistance. We found that pharmacological inhibition of GSK-3 potentiates sorafenib antitumor effect in vitro and in vivo. Our results suggest that combining GSK-3 inhibitor and sorafenib might be a potential new therapeutic approach for RCC treatment.",

keywords = "Glycogen synthase kinase-3, Renal cell carcinoma, Sorafenib, Tyrosine kinase inhibitor",

author = "Hisashi Kawazoe and Bilim, {Vladimir N.} and Ugolkov, {Andrey V.} and Kaori Yuuki and Sei Naito and Akira Nagaoka and Tomoyuki Kato and Yoshihiko Tomita",

year = "2012",

month = jul,

day = "6",

doi = "10.1016/j.bbrc.2012.05.147",

language = "English (US)",

volume = "423",

pages = "490--495",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)

AU - Kawazoe, Hisashi

AU - Bilim, Vladimir N.

AU - Ugolkov, Andrey V.

AU - Yuuki, Kaori

AU - Naito, Sei

AU - Nagaoka, Akira

AU - Kato, Tomoyuki

AU - Tomita, Yoshihiko

PY - 2012/7/6

Y1 - 2012/7/6

N2 - Sorafenib is a multikinase inhibitor approved for the systemic treatment of renal cell carcinoma (RCC). However, sorafenib treatment has a limited effect due to acquired chemoresistance of RCC. Previously, we identified glycogen synthase kinase-3 (GSK-3) as a new therapeutic target in RCC. Here, we observed that sorafenib inhibits proliferation and survival of RCC cells. Significantly, we revealed that sorafenib enhances GSK-3 activity in RCC cells, which could be a potential mechanism of acquired chemoresistance. We found that pharmacological inhibition of GSK-3 potentiates sorafenib antitumor effect in vitro and in vivo. Our results suggest that combining GSK-3 inhibitor and sorafenib might be a potential new therapeutic approach for RCC treatment.

AB - Sorafenib is a multikinase inhibitor approved for the systemic treatment of renal cell carcinoma (RCC). However, sorafenib treatment has a limited effect due to acquired chemoresistance of RCC. Previously, we identified glycogen synthase kinase-3 (GSK-3) as a new therapeutic target in RCC. Here, we observed that sorafenib inhibits proliferation and survival of RCC cells. Significantly, we revealed that sorafenib enhances GSK-3 activity in RCC cells, which could be a potential mechanism of acquired chemoresistance. We found that pharmacological inhibition of GSK-3 potentiates sorafenib antitumor effect in vitro and in vivo. Our results suggest that combining GSK-3 inhibitor and sorafenib might be a potential new therapeutic approach for RCC treatment.

KW - Glycogen synthase kinase-3

KW - Renal cell carcinoma

KW - Sorafenib

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84863314567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863314567&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2012.05.147

DO - 10.1016/j.bbrc.2012.05.147

M3 - Article

C2 - 22683636

AN - SCOPUS:84863314567

VL - 423

SP - 490

EP - 495

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -

GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this